Recent Security Class Actions

Alexion Pharmaceuticals Inc. Common Stock (NASDAQ: ALXN)

Company Name:Alexion Pharmaceuticals Inc. Common Stock
Stock Symbol:NASDAQ: ALXN
Class Period Start:01/30/2014
Class Period End (inclusive):05/26/2017
Filing Deadline:01/16/2017

According to the law firm press release, Alexion, a biopharmaceutical company, develops and commercializes therapeutic products. Among the Company's products is Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder, and atypical hemolytic uremic syndrome (aHUS), a genetic disease.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operational and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Alexion employed improper sales practices with respect to Soliris; (ii) consequently, the Company's revenues from Soliris sales were unlikely to be sustainable; and (iii) as a result of the foregoing, Alexion's public statements were materially false and misleading at all relevant times.